By efain on
Phone
+49 (0)89 700763-0
Email
medical.request@4sc.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=4SC%20AG&spons_ex=Y&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
Acknowledgement
5 days
EA Page
https://www.4sc.com/
Sponsor
4SC AG
EA Policies for Single Patient

4SC focuses on the development of novel small molecule drugs for the treatment of cancer in indications with a high unmet medical need. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s current product pipeline includes two programs in clinical development: resminostat and domatinostat.

We understand the interest of patients in accessing resminostat or domatinostat outside of clinical trials and prior to regulatory approval. However, participation in one of our clinical trials is currently the most appropriate way to access our investigational therapies. 4SC has decided not to offer Expanded Access (EA) to any of our investigational products at this time and will not approve EA requests.

We recognize the need for Expanded Access programs, and we will re-evaluate the status of our policy based on data from ongoing and future clinical trials.
If you have additional questions, please consult your physician or contact medical.request@4sc.com. We anticipate acknowledging receipt of requests sent to this email within five business days.